Magazine Article | August 1, 2022

KemPharm: Converting FDA Complete Response Letters Into New Opportunities

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

It’s not easy to carve out a niche in today’s biopharmaceutical industry. No matter how innovative or unique a pipeline is, or how brilliant and motivating a leader may be, there is always a competitor (or three) waiting in the wings. Fresh off its $12.8 million fire sale acquisition of Danish biopharma Orphazyme, KemPharm, a Celebration, FL-based specialty pharmaceutical company, is betting that its past experiences in rehabbing drugs for regulatory approval — following FDA complete response letters — is a novel capability that can boost the company into a lucrative drug market for rare neurological and CNS disorders.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: